Phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) in adults with newly diagnosed (ND) Philadelphia chromosome–negative (Ph-) B lymphoblastic leukemia (B-ALL).
Noam E. Kopmar(University of Washington), Ryan D. Cassaday(University of Washington), Jason P. Cooper(University of Washington), Erik L. Kimble(University of Washington), Jonathan R. Fromm(University of Iowa), Joshua Veatch(Fred Hutch Cancer Center), Cristina Maria Ghiuzeli(University of Washington), Bart L Scott(Fred Hutch Cancer Center), Mary‐Elizabeth M. Percival(Fred Hutch Cancer Center), Anna B. Halpern(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Raya Mawad(Fred Hutch Cancer Center), Ashtyn Sherrow(Fred Hutch Cancer Center), Noah Pinke(Fred Hutch Cancer Center), T Gooley(Fred Hutch Cancer Center), Roland B. Walter(Fred Hutch Cancer Center), Paul Hendrie(University of Washington), Johnnie J. Orozco(Fred Hutch Cancer Center), Christen Martino(Fred Hutch Cancer Center), Vivian G. Oehler(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 0
Related Papers
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
|Blood|2020|217
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
|Blood|2021|204
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
|Transplantation and Cellular Therapy|2023|144